Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 124

1.

Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.

Greenberg RN, Overton ET, Haas DW, Frank I, Goldman M, von Krempelhuber A, Virgin G, Bädeker N, Vollmar J, Chaplin P.

J Infect Dis. 2013 Mar 1;207(5):749-58. doi: 10.1093/infdis/jis753. Epub 2012 Dec 7.

PMID:
23225902
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.

Cosma A, Nagaraj R, Staib C, Diemer C, Wopfner F, Schätzl H, Busch DH, Sutter G, Goebel FD, Erfle V.

AIDS Res Hum Retroviruses. 2007 Jun;23(6):782-93.

PMID:
17604541
[PubMed - indexed for MEDLINE]
3.

Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.

Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME, Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS; VRC 201/203 Study Team.

Vaccine. 2007 Feb 9;25(8):1513-25. Epub 2006 Nov 7.

PMID:
17126963
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.

Walsh SR, Wilck MB, Dominguez DJ, Zablowsky E, Bajimaya S, Gagne LS, Verrill KA, Kleinjan JA, Patel A, Zhang Y, Hill H, Acharyya A, Fisher DC, Antin JH, Seaman MS, Dolin R, Baden LR.

J Infect Dis. 2013 Jun 15;207(12):1888-97. doi: 10.1093/infdis/jit105. Epub 2013 Mar 12.

PMID:
23482644
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.

Meseda CA, Garcia AD, Kumar A, Mayer AE, Manischewitz J, King LR, Golding H, Merchlinsky M, Weir JP.

Virology. 2005 Sep 1;339(2):164-75.

PMID:
15993917
[PubMed - indexed for MEDLINE]
Free Article
6.

Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice.

Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK.

J Virol. 2007 Aug;81(16):8774-83. Epub 2007 Jun 6.

PMID:
17553867
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.

Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, Schlereth B, Handley A, King L, Hülsemann V, Tzatzaris M, Merkl K, Wulff N, Chaplin P.

Vaccine. 2006 Mar 15;24(12):2065-70. Epub 2005 Nov 28.

PMID:
16337719
[PubMed - indexed for MEDLINE]
8.

Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine.

Phelps AL, Gates AJ, Hillier M, Eastaugh L, Ulaeto DO.

Vaccine. 2007 Jan 2;25(1):34-42. Epub 2006 Aug 1.

PMID:
16950548
[PubMed - indexed for MEDLINE]
9.

Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: a systematic review.

Elizaga ML, Vasan S, Marovich MA, Sato AH, Lawrence DN, Chaitman BR, Frey SE, Keefer MC; MVA Cardiac Safety Working Group.

PLoS One. 2013;8(1):e54407. doi: 10.1371/journal.pone.0054407. Epub 2013 Jan 17.

PMID:
23349878
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.

Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, Lock M, Empig C, Morikawa S, Saijo M, Yokote H, Karem K, Damon I, Perlroth M, Greenberg RN.

J Infect Dis. 2011 Nov;204(9):1395-402. doi: 10.1093/infdis/jir527. Epub 2011 Sep 15.

PMID:
21921208
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Wyatt LS, Earl PL, Eller LA, Moss B.

Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. Epub 2004 Mar 11.

PMID:
15070762
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, Handley A, Mateo L, Siersbol H, Kollaritsch H, Chaplin P.

Vaccine. 2010 Feb 3;28(5):1209-16. doi: 10.1016/j.vaccine.2009.11.030. Epub 2009 Nov 25.

PMID:
19944151
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

Hermanson G, Chun S, Felgner J, Tan X, Pablo J, Nakajima-Sasaki R, Molina DM, Felgner PL, Liang X, Davies DH.

Vaccine. 2012 Jan 11;30(3):614-25. doi: 10.1016/j.vaccine.2011.11.021. Epub 2011 Nov 17.

PMID:
22100890
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Clinical development of Modified Vaccinia virus Ankara vaccines.

Gilbert SC.

Vaccine. 2013 Sep 6;31(39):4241-6. doi: 10.1016/j.vaccine.2013.03.020. Epub 2013 Mar 21. Review.

PMID:
23523410
[PubMed - indexed for MEDLINE]
15.

Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques.

Edghill-Smith Y, Venzon D, Karpova T, McNally J, Nacsa J, Tsai WP, Tryniszewska E, Moniuszko M, Manischewitz J, King LR, Snodgrass SJ, Parrish J, Markham P, Sowers M, Martin D, Lewis MG, Berzofsky JA, Belyakov IM, Moss B, Tartaglia J, Bray M, Hirsch V, Golding H, Franchini G.

J Infect Dis. 2003 Oct 15;188(8):1181-91. Epub 2003 Oct 10.

PMID:
14551889
[PubMed - indexed for MEDLINE]
Free Article
16.

Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.

Harrer E, Bäuerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, Handley A, Tzatzaris M, Vollmar J, Bergmann S, Rittmaier M, Eismann K, Müller S, Kalden JR, Spriewald B, Willbold D, Harrer T.

Antivir Ther. 2005;10(2):285-300.

PMID:
15865223
[PubMed - indexed for MEDLINE]
17.

Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.

McCurdy LH, Rutigliano JA, Johnson TR, Chen M, Graham BS.

J Virol. 2004 Nov;78(22):12471-9.

PMID:
15507634
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.

Wilck MB, Seaman MS, Baden LR, Walsh SR, Grandpre LE, Devoy C, Giri A, Kleinjan JA, Noble LC, Stevenson KE, Kim HT, Dolin R.

J Infect Dis. 2010 May 1;201(9):1361-70. doi: 10.1086/651561. Erratum in: J Infect Dis. 2010 Jul 1;202(1):179.

PMID:
20350191
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

An open-label, single arm, phase III clinical study to evaluate the efficacy and safety of CJ smallpox vaccine in previously vaccinated healthy adults.

Kim NH, Kang YM, Kim G, Choe PG, Song JS, Lee KH, Seong BL, Park WB, Kim NJ, Oh MD.

Vaccine. 2013 Oct 25;31(45):5239-42. doi: 10.1016/j.vaccine.2013.08.071. Epub 2013 Sep 8.

PMID:
24021303
[PubMed - indexed for MEDLINE]
Free Article
20.

Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.

von Sonnenburg F, Perona P, Darsow U, Ring J, von Krempelhuber A, Vollmar J, Roesch S, Baedeker N, Kollaritsch H, Chaplin P.

Vaccine. 2014 Aug 19. pii: S0264-410X(14)01135-9. doi: 10.1016/j.vaccine.2014.08.022. [Epub ahead of print]

PMID:
25149431
[PubMed - as supplied by publisher]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk